Adamis Pharmaceuticals announced that its wholly owned subsidiary DMK Pharmaceuticals Corporation was the recipient of a grant from the National Institute on Alcohol Abuse And Alcoholism of the National Institutes of Health to support the development of a novel bifunctional small molecule for the treatment of Alcohol Use Disorder.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADMP:
- Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
- Adamis participate in White House meeting regarding opioid overdose prevention
- Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
- Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
- Adamis Pharmaceuticals Announces Reverse Stock Split